Summary of Study ST001229

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000822. The data can be accessed directly via it's Project DOI: 10.21228/M8F69D This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001229
Study TitleAquamin and Prevention of Colon Cancer (part-V)
Study TypeMS analysis
Study SummaryWe propose to evaluate microbial and metabolic profiles in baseline and endpoint colonic mucosal, fecal, and serum samples from human patients at risk for CRC and enrolled in a 90-day phase I clinical trial. Patients will receive daily supplementation with calcium alone, a calcium-rich multimineral (Aquamin?), or placebo (maltodextrin) (n=10 per group). We hypothesize that dietary supplementation will correlate with CRC-protective metabolic profiles and that multimineral supplementation will generate more favorable profiles than calcium supplementation alone.
Institute
University of Michigan
DepartmentBiomedical Research Core Facilities
LaboratoryMetabolomics core
Last NameKachman
First NameMaureen
AddressAnn Arbor, MI
Emailmkachman@med.umich.edu
Phone734-232-0842
Submit Date2019-07-24
Num Groups24
Total Subjects18
Study CommentsColorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer related death when both genders are combined. Epidemiologically, calcium intake has been protective against colonic adenomas and even colon cancer. Calcium supplementation has reduced the risk of colon adenoma formation in subjects with a history of previous colon polyps. The utility of calcium supplementation for colon cancer prevention is somewhat modulated by the modest or inconsistent level of protection afforded. Our preliminary data in mice and human enterocyte models shows that dietary supplementation with a multimineral supplement (Aquamin?) containing calcium in combination with 72 measureable trace minerals is more protective against tumors and epithelial growth dysregulation than calcium alone. One potential mechanism, supported by our rodent data, is that multimineral supplementation alters gut microbial populations to generate bile acid and short chain fatty acid (SCFA) profiles that are CRC-protective.
Raw Data AvailableYes
Raw Data File Type(s)d
Analysis Type DetailLC-MS
Release Date2019-09-23
Release Version1
Maureen Kachman Maureen Kachman
https://dx.doi.org/10.21228/M8F69D
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000822
Project DOI:doi: 10.21228/M8F69D
Project Title:Aquamin and Prevention of Colon Cancer
Project Type:MS analysis
Project Summary:Effects of calcium and multi-mineral supplementation on gut microbes and microbially-derived metabolites in patients at risk for colon cancer
Institute:University of Michigan
Department:Pathology
Laboratory:Aslam Lab
Last Name:Aslam
First Name:Muhammad Nadeem
Address:Ann Arbor, MI
Email:mnaslam@umich.edu
Phone:734-936-1897

Subject:

Subject ID:SU001296
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample Source Time Point
SA087005S00031775Feces Baseline
SA087006S00031774Feces Baseline
SA087007S00031773Feces Baseline
SA087008S00031776Feces Baseline
SA087009S00031778Feces Baseline
SA087010S00031779Feces Baseline
SA087011S00031763Feces Baseline
SA087012S00031772Feces Baseline
SA087013S00031777Feces Baseline
SA087014S00031771Feces Baseline
SA087015S00031766Feces Baseline
SA087016S00031765Feces Baseline
SA087017S00031764Feces Baseline
SA087018S00031767Feces Baseline
SA087019S00031768Feces Baseline
SA087020S00031770Feces Baseline
SA087021S00031769Feces Baseline
SA087022S00031780Feces Baseline
SA087023S00031783Feces Day 90
SA087024S00031794Feces Day 90
SA087025S00031793Feces Day 90
SA087026S00031792Feces Day 90
SA087027S00031795Feces Day 90
SA087028S00031796Feces Day 90
SA087029S00031798Feces Day 90
SA087030S00031797Feces Day 90
SA087031S00031791Feces Day 90
SA087032S00031790Feces Day 90
SA087033S00031785Feces Day 90
SA087034S00031784Feces Day 90
SA087035S00031786Feces Day 90
SA087036S00031787Feces Day 90
SA087037S00031789Feces Day 90
SA087038S00031788Feces Day 90
SA087039S00031782Feces Day 90
SA087040S00031781Feces Day 90
SA087041S00031805Serum Baseline
SA087042S00031806Serum Baseline
SA087043S00031807Serum Baseline
SA087044S00031804Serum Baseline
SA087045S00031803Serum Baseline
SA087046S00031801Serum Baseline
SA087047S00031802Serum Baseline
SA087048S00031808Serum Baseline
SA087049S00031809Serum Baseline
SA087050S00031814Serum Baseline
SA087051S00031815Serum Baseline
SA087052S00031816Serum Baseline
SA087053S00031813Serum Baseline
SA087054S00031812Serum Baseline
SA087055S00031810Serum Baseline
SA087056S00031811Serum Baseline
SA087057S00031800Serum Baseline
SA087058S00031799Serum Baseline
SA087059S00031829Serum Day 90
SA087060S00031828Serum Day 90
SA087061S00031827Serum Day 90
SA087062S00031830Serum Day 90
SA087063S00031831Serum Day 90
SA087064S00031818Serum Day 90
SA087065S00031833Serum Day 90
SA087066S00031832Serum Day 90
SA087067S00031826Serum Day 90
SA087068S00031825Serum Day 90
SA087069S00031820Serum Day 90
SA087070S00031819Serum Day 90
SA087071S00031817Serum Day 90
SA087072S00031821Serum Day 90
SA087073S00031822Serum Day 90
SA087074S00031824Serum Day 90
SA087075S00031823Serum Day 90
SA087076S00031834Serum Day 90
SA087077S00031728Tissues Baseline
SA087078S00031740Tissues Baseline
SA087079S00031739Tissues Baseline
SA087080S00031738Tissues Baseline
SA087081S00031741Tissues Baseline
SA087082S00031742Tissues Baseline
SA087083S00031744Tissues Baseline
SA087084S00031743Tissues Baseline
SA087085S00031737Tissues Baseline
SA087086S00031736Tissues Baseline
SA087087S00031731Tissues Baseline
SA087088S00031730Tissues Baseline
SA087089S00031729Tissues Baseline
SA087090S00031732Tissues Baseline
SA087091S00031733Tissues Baseline
SA087092S00031735Tissues Baseline
SA087093S00031734Tissues Baseline
SA087094S00031727Tissues Baseline
SA087095S00031753Tissues Day 90
SA087096S00031749Tissues Day 90
SA087097S00031750Tissues Day 90
SA087098S00031751Tissues Day 90
SA087099S00031748Tissues Day 90
SA087100S00031747Tissues Day 90
SA087101S00031762Tissues Day 90
SA087102S00031746Tissues Day 90
SA087103S00031752Tissues Day 90
SA087104S00031745Tissues Day 90
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 108

Collection:

Collection ID:CO001290
Collection Summary:Not available.
Sample Type:Feces

Treatment:

Treatment ID:TR001311
Treatment Summary:Not available.

Sample Preparation:

Sampleprep ID:SP001304
Sampleprep Summary:Profile of 28 Eicosanoids in plasma or tissue. Eicosanoids are extracted and concentrated using solid phase extraction. The eluant is dried and re-suspended for LCMS separation by RPLC and measurements by ESI- QQQ MRM methods. Analytes are reported as uM or ug/mg (tissue), and CV’s are generally <20%.
Sampleprep Protocol Filename:EX00759 _eicosanoid_protocol.pdf

Combined analysis:

Analysis ID AN002042
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 1290
Column Phenomenex Luna-C18
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Agilent 6490 QQQ
Ion Mode NEGATIVE
Units pmol/mg

Chromatography:

Chromatography ID:CH001482
Instrument Name:Agilent 1290
Column Name:Phenomenex Luna-C18
Chromatography Type:Reversed phase

MS:

MS ID:MS001894
Analysis ID:AN002042
Instrument Name:Agilent 6490 QQQ
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:NA
Ion Mode:NEGATIVE
Acquisition Parameters File:Eis_LunaC18_HA64FA02_AC55_MRM_Halade_2Seg_B10-port1-6-a1-b1.m
Analysis Protocol File:EX00759 - eicosanoid protocol.pdf
  logo